Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity
Open Access
- 28 February 2013
- journal article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 6 (2), 137-156
- https://doi.org/10.1177/1756283x12473675
Abstract
Inflammatory bowel diseases (IBDs) are a group of inflammatory conditions characterized by chronic, uncontrolled inflammation of the gastrointestinal tract. Reported prevalence is high in the United States and northern Europe, while the incidence varies greatly across the rest of Europe. Glucocorticosteroids are the standard treatment for IBD, but due to adverse events their use can be limited. However, new formulations of glucocorticosteroids have been developed to reduce systemic activation. The aim of this review was to assess and summarize the efficacy and safety of new formulations of glucocorticosteroids. A MEDLINE search identified publications focused on new formulations of nonsystemic steroid-based drugs for IBD and benefits and limitations of each of the new glucocorticosteroid formulations were identified. Budesonide has good efficacy and is an established treatment for Crohn’s disease; it has been shown to be beneficial for the induction of remission in these patients, although it is not recommended for the maintenance of induced remission. Glucocorticosteroids are not recommended for the maintenance of remission in patients with IBD. However, a recent study suggested that beclomethasone dipropionate may be effective for prolonged treatment in patients in the postacute phase of Crohn’s disease who were treated with a short course of systemic steroids. The efficacy of fluticasone propionate and prednisolone metasulphobenzoate in IBD is not well established given the small number of patients enrolled in the few published clinical trials. While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted.Keywords
This publication has 70 references indexed in Scilit:
- A retrospective study on a cohort of patients with lymphocytic colitisRevista Española de Enfermedades Digestivas, 2010
- Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysisAlimentary Pharmacology & Therapeutics, 2009
- Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trialAlimentary Pharmacology & Therapeutics, 2005
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2004
- Effect of Budesonide Enema on Remission and Relapse Rate in Distal Ulcerative Colitis and ProctitisScandinavian Journal of Gastroenterology, 2002
- Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's diseaseGut, 2001
- Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's diseaseGut, 1998
- Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month studyAlimentary Pharmacology & Therapeutics, 1998
- Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.Gut, 1996
- Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis.Gut, 1993